Good morning. Elizabeth Cooney sitting in for Ed Silverman, who is covering the J.P. Morgan Healthcare Conference with five STAT colleagues in San Francisco. We have snow flurries here at Boston HQ after yesterday’s temps in the 70s, so you’re not missing a thing, @pharmalot, @adamfeuerstein@damiangarde@rebeccadrobbins@erbrod, and @matthewherper. Meanwhile, we’ve got news for you.

AstraZeneca (AZN) said Monday that it would stop a large clinical study of a fish-oil-derived heart drug, Epanova, after an independent committee concluded it was “unlikely to demonstrate a benefit to patients,” STAT reports. The news removes the most likely competitor for Amarin Pharmaceuticals’ (AMRN) Vascepa, the first heart drug derived from fish oil to be approved to reduce the risk of heart attacks, strokes, and hospitalizations due to heart problems in patients with high levels of triglycerides.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy